ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...
Հիմնական հեղինակներ: | Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E |
---|---|
Ձևաչափ: | Journal article |
Հրապարակվել է: |
Elsevier
2016
|
Նմանատիպ նյութեր
-
ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
: Wilson, J, և այլն
Հրապարակվել է: (2017) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
: Brunner, T, և այլն
Հրապարակվել է: (2008) -
A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
: Brunner, T, և այլն
Հրապարակվել է: (2008) -
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
: Brunner, T, և այլն
Հրապարակվել է: (2008) -
HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
: Unaí Tupinambás, և այլն